APO Research
Talk to an analyst

APO RESEARCH · REPORT

Insulin Drugs for Diabetes

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Insulin Drugs for Diabetes Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

29 December 2025196 pages

Choose your research edition.

Industry ResearchInsulin Drugs for Diabetes Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Insulin Drugs for Diabetes Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Insulin Drugs for Diabetes Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Insulin Drugs for Diabetes Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Insulin Drugs for Diabetes Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Insulin Drugs for Diabetes market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Insulin Drugs for Diabetes is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Insulin Drugs for Diabetes is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Insulin Drugs for Diabetes is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Insulin Drugs for Diabetes is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Insulin Drugs for Diabetes include AstraZeneca, Bayer, Eli Lilly, HTBT, Merck, Novartis, Novo Nordisk, Sanofi and Tonghua Dongbao Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Insulin Drugs for Diabetes market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Insulin Drugs for Diabetes and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Insulin Drugs for Diabetes sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Insulin Drugs for Diabetes market size, projected growth trends, production technologies, key applications, and end-use industries.

Insulin Drugs for Diabetes Segment by Company

AstraZeneca

Bayer

Eli Lilly

HTBT

Merck

Novartis

Novo Nordisk

Sanofi

Tonghua Dongbao Pharmaceutical

Gan & Lee Pharmaceuticals

Kamp Pharmaceuticals

Johnson & Johnson

Wanbang Biopharmaceuticals

Takeda

Insulin Drugs for Diabetes Segment by Type

Ultra-long-acting Insulin

Short-acting Insulin

Rapid-acting Insulin

Long-acting Insulin

Intermediate-acting Insulin

Insulin Drugs for Diabetes Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

Insulin Drugs for Diabetes Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Insulin Drugs for Diabetes market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Insulin Drugs for Diabetes and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Insulin Drugs for Diabetes.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Insulin Drugs for Diabetes market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Insulin Drugs for Diabetes manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Insulin Drugs for Diabetes in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Insulin Drugs for Diabetes in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Insulin Drugs for Diabetes Industry Trends Table 2. Insulin Drugs for Diabetes Industry Drivers Table 3. Insulin Drugs for Diabetes Industry Opportunities and Challenges Table 4. Insulin Drugs for Diabetes Industry Restraints Table 5. Global Insulin Drugs for Diabetes Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Insulin Drugs for Diabetes Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Insulin Drugs for Diabetes Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Insulin Drugs for Diabetes Sales Market Share by Manufacturers Table 9. Global Insulin Drugs for Diabetes Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Insulin Drugs for Diabetes Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Insulin Drugs for Diabetes Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Insulin Drugs for Diabetes Manufacturers, Product Type & Application Table 13. Global Insulin Drugs for Diabetes Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Insulin Drugs for Diabetes by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Ultra-long-acting Insulin Table 17. Major Manufacturers of Short-acting Insulin Table 18. Major Manufacturers of Rapid-acting Insulin Table 19. Major Manufacturers of Long-acting Insulin Table 20. Major Manufacturers of Intermediate-acting Insulin Table 21. Global Insulin Drugs for Diabetes Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Insulin Drugs for Diabetes Sales by Type (2021-2026) & (K Units) Table 23. Global Insulin Drugs for Diabetes Sales by Type (2027-2032) & (K Units) Table 24. Global Insulin Drugs for Diabetes Sales Market Share by Type (2021-2026) Table 25. Global Insulin Drugs for Diabetes Sales Market Share by Type (2027-2032) Table 26. Global Insulin Drugs for Diabetes Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Insulin Drugs for Diabetes Revenue by Type (2021-2026) & (K Units) Table 28. Global Insulin Drugs for Diabetes Revenue by Type (2027-2032) & (K Units) Table 29. Global Insulin Drugs for Diabetes Revenue Market Share by Type (2021-2026) Table 30. Global Insulin Drugs for Diabetes Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Hospital and Clinic Table 32. Major Manufacturers of Retail Pharmacies Table 33. Major Manufacturers of Other Table 34. Global Insulin Drugs for Diabetes Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Insulin Drugs for Diabetes Sales by Application (2021-2026) & (K Units) Table 36. Global Insulin Drugs for Diabetes Sales by Application (2027-2032) & (K Units) Table 37. Global Insulin Drugs for Diabetes Sales Market Share by Application (2021-2026) Table 38. Global Insulin Drugs for Diabetes Sales Market Share by Application (2027-2032) Table 39. Global Insulin Drugs for Diabetes Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Insulin Drugs for Diabetes Revenue by Application (2021-2026) & (K Units) Table 41. Global Insulin Drugs for Diabetes Revenue by Application (2027-2032) & (K Units) Table 42. Global Insulin Drugs for Diabetes Revenue Market Share by Application (2021-2026) Table 43. Global Insulin Drugs for Diabetes Revenue Market Share by Application (2027-2032) Table 44. Global Insulin Drugs for Diabetes Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Insulin Drugs for Diabetes Sales by Region (2021-2026) & (K Units) Table 46. Global Insulin Drugs for Diabetes Sales Market Share by Region (2021-2026) Table 47. Global Insulin Drugs for Diabetes Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Insulin Drugs for Diabetes Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Insulin Drugs for Diabetes Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Insulin Drugs for Diabetes Sales by Country (2021-2026) & (K Units) Table 51. North America Insulin Drugs for Diabetes Sales by Country (2027-2032) & (K Units) Table 52. Europe Insulin Drugs for Diabetes Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Insulin Drugs for Diabetes Sales by Country (2021-2026) & (K Units) Table 54. Europe Insulin Drugs for Diabetes Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Insulin Drugs for Diabetes Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Insulin Drugs for Diabetes Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Insulin Drugs for Diabetes Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Insulin Drugs for Diabetes Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Insulin Drugs for Diabetes Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Insulin Drugs for Diabetes Sales by Country (2027-2032) & (K Units) Table 61. Global Insulin Drugs for Diabetes Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Insulin Drugs for Diabetes Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Insulin Drugs for Diabetes Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Insulin Drugs for Diabetes Revenue Market Share by Region (2021-2026) Table 65. Global Insulin Drugs for Diabetes Revenue Market Share by Region (2027-2032) Table 66. AstraZeneca Company Information Table 67. AstraZeneca Business Overview Table 68. AstraZeneca Insulin Drugs for Diabetes Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. AstraZeneca Insulin Drugs for Diabetes Product Portfolio Table 70. AstraZeneca Recent Development Table 71. Bayer Company Information Table 72. Bayer Business Overview Table 73. Bayer Insulin Drugs for Diabetes Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Bayer Insulin Drugs for Diabetes Product Portfolio Table 75. Bayer Recent Development Table 76. Eli Lilly Company Information Table 77. Eli Lilly Business Overview Table 78. Eli Lilly Insulin Drugs for Diabetes Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Eli Lilly Insulin Drugs for Diabetes Product Portfolio Table 80. Eli Lilly Recent Development Table 81. HTBT Company Information Table 82. HTBT Business Overview Table 83. HTBT Insulin Drugs for Diabetes Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. HTBT Insulin Drugs for Diabetes Product Portfolio Table 85. HTBT Recent Development Table 86. Merck Company Information Table 87. Merck Business Overview Table 88. Merck Insulin Drugs for Diabetes Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Merck Insulin Drugs for Diabetes Product Portfolio Table 90. Merck Recent Development Table 91. Novartis Company Information Table 92. Novartis Business Overview Table 93. Novartis Insulin Drugs for Diabetes Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Novartis Insulin Drugs for Diabetes Product Portfolio Table 95. Novartis Recent Development Table 96. Novo Nordisk Company Information Table 97. Novo Nordisk Business Overview Table 98. Novo Nordisk Insulin Drugs for Diabetes Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Novo Nordisk Insulin Drugs for Diabetes Product Portfolio Table 100. Novo Nordisk Recent Development Table 101. Sanofi Company Information Table 102. Sanofi Business Overview Table 103. Sanofi Insulin Drugs for Diabetes Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Sanofi Insulin Drugs for Diabetes Product Portfolio Table 105. Sanofi Recent Development Table 106. Tonghua Dongbao Pharmaceutical Company Information Table 107. Tonghua Dongbao Pharmaceutical Business Overview Table 108. Tonghua Dongbao Pharmaceutical Insulin Drugs for Diabetes Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Tonghua Dongbao Pharmaceutical Insulin Drugs for Diabetes Product Portfolio Table 110. Tonghua Dongbao Pharmaceutical Recent Development Table 111. Gan & Lee Pharmaceuticals Company Information Table 112. Gan & Lee Pharmaceuticals Business Overview Table 113. Gan & Lee Pharmaceuticals Insulin Drugs for Diabetes Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Gan & Lee Pharmaceuticals Insulin Drugs for Diabetes Product Portfolio Table 115. Gan & Lee Pharmaceuticals Recent Development Table 116. Kamp Pharmaceuticals Company Information Table 117. Kamp Pharmaceuticals Business Overview Table 118. Kamp Pharmaceuticals Insulin Drugs for Diabetes Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Kamp Pharmaceuticals Insulin Drugs for Diabetes Product Portfolio Table 120. Kamp Pharmaceuticals Recent Development Table 121. Johnson & Johnson Company Information Table 122. Johnson & Johnson Business Overview Table 123. Johnson & Johnson Insulin Drugs for Diabetes Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Johnson & Johnson Insulin Drugs for Diabetes Product Portfolio Table 125. Johnson & Johnson Recent Development Table 126. Wanbang Biopharmaceuticals Company Information Table 127. Wanbang Biopharmaceuticals Business Overview Table 128. Wanbang Biopharmaceuticals Insulin Drugs for Diabetes Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Wanbang Biopharmaceuticals Insulin Drugs for Diabetes Product Portfolio Table 130. Wanbang Biopharmaceuticals Recent Development Table 131. Takeda Company Information Table 132. Takeda Business Overview Table 133. Takeda Insulin Drugs for Diabetes Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Takeda Insulin Drugs for Diabetes Product Portfolio Table 135. Takeda Recent Development Table 136. Key Raw Materials Table 137. Raw Materials Key Suppliers Table 138. Insulin Drugs for Diabetes Distributors List Table 139. Insulin Drugs for Diabetes Customers List Table 140. Research Programs/Design for This Report Table 141. Authors List of This Report Table 142. Secondary Sources Table 143. Primary Sources List of Figures Figure 1. Insulin Drugs for Diabetes Product Image Figure 2. Global Insulin Drugs for Diabetes Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Insulin Drugs for Diabetes Market Size (2021-2032) & (US$ Million) Figure 4. Global Insulin Drugs for Diabetes Sales (2021-2032) & (K Units) Figure 5. Global Insulin Drugs for Diabetes Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Insulin Drugs for Diabetes Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Ultra-long-acting Insulin Image Figure 9. Short-acting Insulin Image Figure 10. Rapid-acting Insulin Image Figure 11. Long-acting Insulin Image Figure 12. Intermediate-acting Insulin Image Figure 13. Global Insulin Drugs for Diabetes Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Insulin Drugs for Diabetes Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Insulin Drugs for Diabetes Sales Market Share by Type (2021-2032) Figure 16. Global Insulin Drugs for Diabetes Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Insulin Drugs for Diabetes Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Insulin Drugs for Diabetes Revenue Market Share by Type (2021-2032) Figure 19. Hospital and Clinic Image Figure 20. Retail Pharmacies Image Figure 21. Other Image Figure 22. Global Insulin Drugs for Diabetes Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Insulin Drugs for Diabetes Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Insulin Drugs for Diabetes Sales Market Share by Application (2021-2032) Figure 25. Global Insulin Drugs for Diabetes Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Insulin Drugs for Diabetes Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Insulin Drugs for Diabetes Revenue Market Share by Application (2021-2032) Figure 28. North America Insulin Drugs for Diabetes Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Insulin Drugs for Diabetes Sales Market Share by Country (2021-2032) Figure 30. U.S. Insulin Drugs for Diabetes Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Insulin Drugs for Diabetes Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Insulin Drugs for Diabetes Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Insulin Drugs for Diabetes Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Insulin Drugs for Diabetes Sales Market Share by Country (2021-2032) Figure 35. Germany Insulin Drugs for Diabetes Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Insulin Drugs for Diabetes Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Insulin Drugs for Diabetes Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Insulin Drugs for Diabetes Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Insulin Drugs for Diabetes Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Insulin Drugs for Diabetes Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Insulin Drugs for Diabetes Sales Market Share by Country (2021-2032) Figure 42. China Insulin Drugs for Diabetes Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Insulin Drugs for Diabetes Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Insulin Drugs for Diabetes Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Insulin Drugs for Diabetes Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Insulin Drugs for Diabetes Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Insulin Drugs for Diabetes Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Insulin Drugs for Diabetes Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Insulin Drugs for Diabetes Sales Market Share by Country (2021-2032) Figure 50. Brazil Insulin Drugs for Diabetes Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Insulin Drugs for Diabetes Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Insulin Drugs for Diabetes Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Insulin Drugs for Diabetes Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Insulin Drugs for Diabetes Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Insulin Drugs for Diabetes Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Insulin Drugs for Diabetes Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Insulin Drugs for Diabetes Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Insulin Drugs for Diabetes Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Insulin Drugs for Diabetes Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Insulin Drugs for Diabetes Revenue (2021-2032) & (US$ Million) Figure 61. North America Insulin Drugs for Diabetes Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Insulin Drugs for Diabetes Revenue (2021-2032) & (US$ Million) Figure 63. Europe Insulin Drugs for Diabetes Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Insulin Drugs for Diabetes Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Insulin Drugs for Diabetes Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Insulin Drugs for Diabetes Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Insulin Drugs for Diabetes Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Insulin Drugs for Diabetes Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Insulin Drugs for Diabetes Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Ultra-long-acting Insulin
  • Short-acting Insulin
  • Rapid-acting Insulin
  • Long-acting Insulin
  • Intermediate-acting Insulin
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • AstraZeneca
  • Bayer
  • Eli Lilly
  • HTBT
  • Merck
  • Novartis
  • Novo Nordisk
  • Sanofi
  • Tonghua Dongbao Pharmaceutical
  • Gan & Lee Pharmaceuticals
  • Kamp Pharmaceuticals
  • Johnson & Johnson
  • Wanbang Biopharmaceuticals
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Insulin Drugs for Diabetes Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Insulin Drugs for Diabetes Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Insulin Drugs for Diabetes Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Insulin Drugs for Diabetes Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Insulin Drugs for Diabetes Market Dynamics
  1. 2.1 Insulin Drugs for Diabetes Industry Trends
  2. 2.2 Insulin Drugs for Diabetes Industry Drivers
  3. 2.3 Insulin Drugs for Diabetes Industry Opportunities and Challenges
  4. 2.4 Insulin Drugs for Diabetes Industry Restraints
3 Insulin Drugs for Diabetes Market by Manufacturers
  1. 3.1 Global Insulin Drugs for Diabetes Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Insulin Drugs for Diabetes Sales by Manufacturers (2021-2026)
  3. 3.3 Global Insulin Drugs for Diabetes Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Insulin Drugs for Diabetes Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Insulin Drugs for Diabetes Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Insulin Drugs for Diabetes Manufacturers, Product Type & Application
  7. 3.7 Global Insulin Drugs for Diabetes Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Insulin Drugs for Diabetes Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Insulin Drugs for Diabetes Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Insulin Drugs for Diabetes Tier 1, Tier 2, and Tier 3
4 Insulin Drugs for Diabetes Market by Type
  1. 4.1 Insulin Drugs for Diabetes Type Introduction
  2. 4.1.1 Ultra-long-acting Insulin
  3. 4.1.2 Short-acting Insulin
  4. 4.1.3 Rapid-acting Insulin
  5. 4.1.4 Long-acting Insulin
  6. 4.1.5 Intermediate-acting Insulin
  7. 4.2 Global Insulin Drugs for Diabetes Sales by Type
  8. 4.2.1 Global Insulin Drugs for Diabetes Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Insulin Drugs for Diabetes Sales by Type (2021-2032)
  10. 4.2.3 Global Insulin Drugs for Diabetes Sales Market Share by Type (2021-2032)
  11. 4.3 Global Insulin Drugs for Diabetes Revenue by Type
  12. 4.3.1 Global Insulin Drugs for Diabetes Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Insulin Drugs for Diabetes Revenue by Type (2021-2032)
  14. 4.3.3 Global Insulin Drugs for Diabetes Revenue Market Share by Type (2021-2032)
5 Insulin Drugs for Diabetes Market by Application
  1. 5.1 Insulin Drugs for Diabetes Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Other
  5. 5.2 Global Insulin Drugs for Diabetes Sales by Application
  6. 5.2.1 Global Insulin Drugs for Diabetes Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Insulin Drugs for Diabetes Sales by Application (2021-2032)
  8. 5.2.3 Global Insulin Drugs for Diabetes Sales Market Share by Application (2021-2032)
  9. 5.3 Global Insulin Drugs for Diabetes Revenue by Application
  10. 5.3.1 Global Insulin Drugs for Diabetes Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Insulin Drugs for Diabetes Revenue by Application (2021-2032)
  12. 5.3.3 Global Insulin Drugs for Diabetes Revenue Market Share by Application (2021-2032)
6 Global Insulin Drugs for Diabetes Sales by Region
  1. 6.1 Global Insulin Drugs for Diabetes Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Insulin Drugs for Diabetes Sales by Region (2021-2032)
  3. 6.2.1 Global Insulin Drugs for Diabetes Sales by Region (2021-2026)
  4. 6.2.2 Global Insulin Drugs for Diabetes Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Insulin Drugs for Diabetes Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Insulin Drugs for Diabetes Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Insulin Drugs for Diabetes Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Insulin Drugs for Diabetes Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Insulin Drugs for Diabetes Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Insulin Drugs for Diabetes Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Insulin Drugs for Diabetes Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Insulin Drugs for Diabetes Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Insulin Drugs for Diabetes Revenue by Region
  1. 7.1 Global Insulin Drugs for Diabetes Revenue by Region
  2. 7.1.1 Global Insulin Drugs for Diabetes Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Insulin Drugs for Diabetes Revenue by Region (2021-2026)
  4. 7.1.3 Global Insulin Drugs for Diabetes Revenue by Region (2027-2032)
  5. 7.1.4 Global Insulin Drugs for Diabetes Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Insulin Drugs for Diabetes Revenue (2021-2032)
  8. 7.2.2 North America Insulin Drugs for Diabetes Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Insulin Drugs for Diabetes Revenue (2021-2032)
  11. 7.3.2 Europe Insulin Drugs for Diabetes Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Insulin Drugs for Diabetes Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Insulin Drugs for Diabetes Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Insulin Drugs for Diabetes Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Insulin Drugs for Diabetes Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 AstraZeneca
  2. 8.1.1 AstraZeneca Company Information
  3. 8.1.2 AstraZeneca Business Overview
  4. 8.1.3 AstraZeneca Insulin Drugs for Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AstraZeneca Insulin Drugs for Diabetes Product Portfolio
  6. 8.1.5 AstraZeneca Recent Developments
  7. 8.2 Bayer
  8. 8.2.1 Bayer Company Information
  9. 8.2.2 Bayer Business Overview
  10. 8.2.3 Bayer Insulin Drugs for Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bayer Insulin Drugs for Diabetes Product Portfolio
  12. 8.2.5 Bayer Recent Developments
  13. 8.3 Eli Lilly
  14. 8.3.1 Eli Lilly Company Information
  15. 8.3.2 Eli Lilly Business Overview
  16. 8.3.3 Eli Lilly Insulin Drugs for Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly Insulin Drugs for Diabetes Product Portfolio
  18. 8.3.5 Eli Lilly Recent Developments
  19. 8.4 HTBT
  20. 8.4.1 HTBT Company Information
  21. 8.4.2 HTBT Business Overview
  22. 8.4.3 HTBT Insulin Drugs for Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 HTBT Insulin Drugs for Diabetes Product Portfolio
  24. 8.4.5 HTBT Recent Developments
  25. 8.5 Merck
  26. 8.5.1 Merck Company Information
  27. 8.5.2 Merck Business Overview
  28. 8.5.3 Merck Insulin Drugs for Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Merck Insulin Drugs for Diabetes Product Portfolio
  30. 8.5.5 Merck Recent Developments
  31. 8.6 Novartis
  32. 8.6.1 Novartis Company Information
  33. 8.6.2 Novartis Business Overview
  34. 8.6.3 Novartis Insulin Drugs for Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novartis Insulin Drugs for Diabetes Product Portfolio
  36. 8.6.5 Novartis Recent Developments
  37. 8.7 Novo Nordisk
  38. 8.7.1 Novo Nordisk Company Information
  39. 8.7.2 Novo Nordisk Business Overview
  40. 8.7.3 Novo Nordisk Insulin Drugs for Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Novo Nordisk Insulin Drugs for Diabetes Product Portfolio
  42. 8.7.5 Novo Nordisk Recent Developments
  43. 8.8 Sanofi
  44. 8.8.1 Sanofi Company Information
  45. 8.8.2 Sanofi Business Overview
  46. 8.8.3 Sanofi Insulin Drugs for Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sanofi Insulin Drugs for Diabetes Product Portfolio
  48. 8.8.5 Sanofi Recent Developments
  49. 8.9 Tonghua Dongbao Pharmaceutical
  50. 8.9.1 Tonghua Dongbao Pharmaceutical Company Information
  51. 8.9.2 Tonghua Dongbao Pharmaceutical Business Overview
  52. 8.9.3 Tonghua Dongbao Pharmaceutical Insulin Drugs for Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Tonghua Dongbao Pharmaceutical Insulin Drugs for Diabetes Product Portfolio
  54. 8.9.5 Tonghua Dongbao Pharmaceutical Recent Developments
  55. 8.10 Gan & Lee Pharmaceuticals
  56. 8.10.1 Gan & Lee Pharmaceuticals Company Information
  57. 8.10.2 Gan & Lee Pharmaceuticals Business Overview
  58. 8.10.3 Gan & Lee Pharmaceuticals Insulin Drugs for Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Gan & Lee Pharmaceuticals Insulin Drugs for Diabetes Product Portfolio
  60. 8.10.5 Gan & Lee Pharmaceuticals Recent Developments
  61. 8.11 Kamp Pharmaceuticals
  62. 8.11.1 Kamp Pharmaceuticals Company Information
  63. 8.11.2 Kamp Pharmaceuticals Business Overview
  64. 8.11.3 Kamp Pharmaceuticals Insulin Drugs for Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Kamp Pharmaceuticals Insulin Drugs for Diabetes Product Portfolio
  66. 8.11.5 Kamp Pharmaceuticals Recent Developments
  67. 8.12 Johnson & Johnson
  68. 8.12.1 Johnson & Johnson Company Information
  69. 8.12.2 Johnson & Johnson Business Overview
  70. 8.12.3 Johnson & Johnson Insulin Drugs for Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Johnson & Johnson Insulin Drugs for Diabetes Product Portfolio
  72. 8.12.5 Johnson & Johnson Recent Developments
  73. 8.13 Wanbang Biopharmaceuticals
  74. 8.13.1 Wanbang Biopharmaceuticals Company Information
  75. 8.13.2 Wanbang Biopharmaceuticals Business Overview
  76. 8.13.3 Wanbang Biopharmaceuticals Insulin Drugs for Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Wanbang Biopharmaceuticals Insulin Drugs for Diabetes Product Portfolio
  78. 8.13.5 Wanbang Biopharmaceuticals Recent Developments
  79. 8.14 Takeda
  80. 8.14.1 Takeda Company Information
  81. 8.14.2 Takeda Business Overview
  82. 8.14.3 Takeda Insulin Drugs for Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Takeda Insulin Drugs for Diabetes Product Portfolio
  84. 8.14.5 Takeda Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Insulin Drugs for Diabetes Value Chain Analysis
  2. 9.1.1 Insulin Drugs for Diabetes Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Insulin Drugs for Diabetes Production Mode & Process
  6. 9.2 Insulin Drugs for Diabetes Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Insulin Drugs for Diabetes Distributors
  9. 9.2.3 Insulin Drugs for Diabetes Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst